info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Gestational Trophoblastic Disease Market Size

ID: MRFR//5096-HCR | 100 Pages | Author: Rahul Gotadki| October 2024

Maternal age is a key element impacting the improvement of GTD, with higher frequency rates saw in ladies at the limits of regenerative age. Segment patterns, including the age movement of the female population, add to the market elements of GTD.
Mechanical movements in demonstrative strategies, for example, ultrasound imaging and molecular testing, influence the early location and analysis of GTD. Further developed demonstrative precision adds to ideal intervention and impacts market patterns.
Advancing treatment conventions for GTD, including chemotherapy, surgery, and follow-up care, impact the market. Progresses in treatment choices, individualized care plans, and the presentation of novel helpful methodologies add to the general market elements.
Varieties in medical care foundation, including admittance to gynecological administrations, influence the determination and management of GTD. Deep rooted medical services frameworks might prompt higher inference rates and better therapy results, affecting market elements.
The degree of health care coverage inclusion for GTD-related clinical intercessions impacts patient entry. Insurance contracts and repayment components influence market elements by influencing the moderateness of indicative tests and medicines.
The accessibility of psychosocial support administrations for ladies impacted by GTD impacts market elements. Stable consideration, guiding, and patient support drives add to all-encompassing medical care approaches and effect patient results.
The interconnectedness of medical services frameworks all around the world works with the trading of information and ability in overseeing GTD. Joint efforts, data sharing, and worldwide medical services drives add to the general market elements.

Global Gestational Trophoblastic Disease Market Overview


Gestational Trophoblastic Disease Market Size was valued at USD 1.46 Billion in 2023. The Global Gestational Trophoblastic Disease industry is projected to grow from USD 1.53 Billion in 2024 to USD 3.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.84% during the forecast period (2024 - 2032).


Gestational trophoblastic disease (GTD) comprises a group of interrelated ailments that arise from the placental trophoblastic tissue. This can occur after normal or abnormal fertilization and is characterized by a distinct tumor marker, β-subunit of human chorionic gonadotrophin (β HCG).


Increase in risk factors affecting this spectrum of disease is expected to drive the growth of the market. These risk factors include high maternal age, the rise in ectopic pregnancies and excessive smoking. According to the American Lung Association, cigarette smoking kills an estimated 201,770 women annually in the US. Also, the increase in innovations in the field of oncology in anticipated to contribute significantly to the growth in this market.
For instance, as on 11th October 2018, Bristol-Myers Squibb Company and Compugen Ltd. announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. Compugen Ltd., being a therapeutic discovery company, consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.


Moreover, high risk of recurrence of the tumors, even after single or multi-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hamper the market growth. Also, mismanagement of the disease with unclear or no guidelines in different regions may curb the growth of gestational trophoblastic disease during the assessment period. Some of the forms of the gestational trophoblastic disease start to show symptoms only after it reaches stage III. At this stage, it might have already spread to other parts of the body. According to the American Society of Clinical Oncology (ASCO), about 35% of women with placental-site trophoblastic tumor have had the cancer spread before it was diagnosed.


Gestational Trophoblastic Disease Market Segmentation


The gestational trophoblastic disease market has been segmented into type, treatment, and end user.


The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.


The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.


The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.


the market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.


The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.


The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.


Gestational Trophoblastic Disease Market Key Players


Some of the key players in the gestational trophoblastic disease market are:


  • Teva Pharmaceutical Industries Ltd.,

  • Hikma Pharmaceuticals PLC,

  • Pfizer Inc.,

  • Bristol-Myers Squibb Company,

  • Antares Pharma,

  • Mylan N.V.,

  • Novartis AG,

  • BP Pharmaceuticals Laboratories Company,

  • Fresenius Kabi AG,

  • Accord Healthcare, Inc.,

  • Eli Lilly and Company,

  • Sanofi,

  • Bayer AG,

  • Amgen Inc. and Merck


Gestational Trophoblastic Disease Market Regional Analysis


Geographically, the Americas is projected to dominate the gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.


Europe is expected to hold the second largest position in the gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.


On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.


Gestational Trophoblastic Disease Market, by Type



  • Hydatidiform mole

  • Complete

  • Partial

  • Invasive

  • Choriocarcinoma

  • Placental-site trophoblastic tumor

  • Epithelioid trophoblastic tumor

  • Others


Gestational Trophoblastic Disease Market, by Treatment



  • Surgery

  • Abdominal hysterectomy

  • Vaginal hysterectomy    



  • Chemotherapy

  • Suction dilation and curettage (D&C)

  • Radiation Therapy


    • External beam radiation therapy



Gestational Trophoblastic Disease Market, by End user



  • Hospital and clinics

  • Diagnostic centers

  • Others


Gestational Trophoblastic Disease Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa




  • Middle East




  • Africa



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.